RLYB

RallybioD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$15.00

-7.6% vs current

Most likely

Base case

50%

Probability

Target price

$8.50

-47.6% vs current

B-

Bear case

30%

Probability

Target price

$4.00

-75.4% vs current

AI sentiment snapshot

Latest data as of 2026-04-06

AI commentary

Market tone is cautious-to-neutral: recent positive Phase 1 data created hopeful headlines but disclosure of the CMO departure increased execution risk [#IR-undated] [#8-K-2026-03-31]. Analyst coverage is thin with consensus near the current price, suggesting limited conviction among sell-side participants [#SERP-1] [#SERP-3].

RankAlpha Sentiment AI - 2026-04-06

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-07-05catalystNear-term leadership gap after Chief Medical Officer departureHigh impact

Rallybio disclosed the immediate departure of its CMO (Steven Ryder, M.D.) on 2026-03-31; this personnel change could slow clinical program execution or increase perceived execution risk in the coming quarters [#8-K-2026-03-31].

2027-04-06catalystAdvancement of RLYB116 development after positive Phase 1 dataHigh impact

Rallybio reported positive Phase 1 data for RLYB116 demonstrating complete and sustained inhibition of terminal complement; progression decisions (e.g., IND-enabling activities or partnered development) over the next 12 months could materially re-rate value if a clear path to a Phase 2 program or partner emerges [#IR-undated].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-06 • Updated nightlySource: Internal modelMethodology